Grandmother and granddaughter smiling, representing Boston Scientific's commitment to redefining liver cancer care for patients.

THERASPHERETM Y-90 THERAPY

Because life matters

Redefining liver cancer care
for 20 years and beyond

The 20 years experience of TheraSphere™ Y-90 Therapy redefined the lives of 30,000 liver cancer patients in Europe.
Because life matters…

Backed by two decades of robust clinical evidence, TheraSphere™ is the only therapy proven to downstage HCC*, expanding curative options and improving overall survival for liver cancer patients.

Redefining liver cancer care

Learn more about the past, present, and future of TheraSphereTM Y-90 therapy and the key clinical milestones that have led the way in the last 20 years.

Setting the standards in liver cancer care

TheraSphere™ is supported by guidelines for effective HCC management1-4  and never ceases to expand its solid range of scientific evidence.

Discover our impact on guidelines and clinical evidence

Your choice matters

Experience matters

For over 20 years, we have been investing in scientific evidence for TheraSphere™ Y-90 Therapy, proving efficacy throughout HCC treatment pathway. Today, 40 ongoing trials.

Hand on shoulder giving support, expressing that if experience matters, you should choose TheraSphere.

Power matters

TheraSphere™ glass microspheres deliver an unparalleled 4,000 Bq per sphere, a specifically engineered power to effectively treat all liver cancer tumours.

Hands together showing the power of unity, expressing that if power matters, you should choose TheraSphere.

Safety matters

TheraSphere™ preserves healthy tissues while safely maximising tumour dose and minimising embolic load.

Two people hugging, expressing that if safety matters, you should choose TheraSphere.

Precision matters

TheraSphere™ with personalised dosimetry ensures precise treatment planning for accurate, predictable and reproducible clinical outcomes.

Carefully placing some flowers, expressing that if precision matters, you should choose TheraSphere.
Explore TheraSphere and the full range of Boston Scientific's SIRT portfolio.

SIRT Portfolio

Dive into our personalised dosimetry solutions and uncover TheraSphere™ Y-90 Therapy, the only SIRT (Selective Internal Radiation Therapy) backed by 20 years of proven experience.

Discover products 

icon-person-with-headset

Contact a sales representative
Do you have questions? Want to learn more about our products and services?

Request a sales representative
icon-document-with-magnifying-glass

Clinical evidence
Our interventional oncology portfolio is backed by more than 20 years of clinical research

Discover the latest data
Icon representing get updates

Stay up-to-date
Receive emails about the latest interventional oncology news, innovations and events.

Sign up for updates

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

*Hepatocellular Carcinoma

1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022; 76(3): 681-93.

2. EASL. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2): 315-374.

3. Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(5):491-506.

4. Kodali S, Kulik L, D'Allessio A, et al. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma. Liver Transpl. 2025;31(6):815-831.